<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Health News and Scoops &#187; food and drug administration fda</title>
	<atom:link href="http://blogjobs.biz/tag/food-and-drug-administration-fda/feed/" rel="self" type="application/rss+xml" />
	<link>http://blogjobs.biz</link>
	<description>Get the Latest Breakthroughs in Health</description>
	<lastBuildDate>Wed, 08 Feb 2012 19:57:07 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.1</generator>
		<item>
		<title>U.S. FDA approves drug to treat rare form of cystic fibrosis</title>
		<link>http://blogjobs.biz/2012/02/u-u-s-fda-approves-drug-to-treat-rare-form-of-cystic-fibrosis/</link>
		<comments>http://blogjobs.biz/2012/02/u-u-s-fda-approves-drug-to-treat-rare-form-of-cystic-fibrosis/#comments</comments>
		<pubDate>Wed, 01 Feb 2012 04:25:45 +0000</pubDate>
		<dc:creator>Doctor Medical</dc:creator>
				<category><![CDATA[Health News]]></category>
		<category><![CDATA[caucasian population]]></category>
		<category><![CDATA[cftr gene]]></category>
		<category><![CDATA[cystic fibrosis]]></category>
		<category><![CDATA[digestive problems]]></category>
		<category><![CDATA[digestive tract]]></category>
		<category><![CDATA[fatal genetic disease]]></category>
		<category><![CDATA[fda commissioner]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[gene function]]></category>
		<category><![CDATA[genetic disorder]]></category>
		<category><![CDATA[genetic makeup]]></category>
		<category><![CDATA[increasing weight]]></category>
		<category><![CDATA[lung function]]></category>
		<category><![CDATA[respiratory tract infection]]></category>
		<category><![CDATA[stomach ache]]></category>
		<category><![CDATA[thick mucus]]></category>
		<category><![CDATA[upper respiratory tract]]></category>
		<category><![CDATA[upper respiratory tract infection]]></category>
		<category><![CDATA[water transport]]></category>

		<guid isPermaLink="false">http://blogjobs.biz/?p=7881</guid>
		<description><![CDATA[The U.S. Food and Drug Administration (FDA) approved Kalydeco for the treatment of a rare form of cystic fibrosis in patients aged six years and older who have the specific G551D mutation in the CFTR gene<div class="addthis_toolbox addthis_default_style addthis_32x32_style" addthis:url='http://blogjobs.biz/2012/02/u-u-s-fda-approves-drug-to-treat-rare-form-of-cystic-fibrosis/' addthis:title='U.S. FDA approves drug to treat rare form of cystic fibrosis' ><a class="addthis_button_google_plusone"></a><a class="addthis_button_facebook_like"></a><a class="addthis_button_stumbleupon"></a><a class="addthis_button_digg"></a><a class="addthis_button_compact"></a></div>]]></description>
		<wfw:commentRss>http://blogjobs.biz/2012/02/u-u-s-fda-approves-drug-to-treat-rare-form-of-cystic-fibrosis/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Keppra XR Dosage Strength Tablets to Combat Partial One-Set Seizures</title>
		<link>http://blogjobs.biz/2011/07/keppra-xr-dosage-strength-tablets-to-combat-partial-one-set-seizures/</link>
		<comments>http://blogjobs.biz/2011/07/keppra-xr-dosage-strength-tablets-to-combat-partial-one-set-seizures/#comments</comments>
		<pubDate>Fri, 29 Jul 2011 05:03:32 +0000</pubDate>
		<dc:creator>Doctor Medical</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Health News]]></category>
		<category><![CDATA[Medication]]></category>
		<category><![CDATA[american epilepsy society]]></category>
		<category><![CDATA[baseline period]]></category>
		<category><![CDATA[dosage]]></category>
		<category><![CDATA[Epilepsy]]></category>
		<category><![CDATA[epilepsy patients]]></category>
		<category><![CDATA[food and drug]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[increments]]></category>
		<category><![CDATA[Keppra]]></category>
		<category><![CDATA[levetiracetam]]></category>
		<category><![CDATA[medication regimen]]></category>
		<category><![CDATA[mg tablet]]></category>
		<category><![CDATA[minimal side effects]]></category>
		<category><![CDATA[neurology]]></category>
		<category><![CDATA[partial onset seizures]]></category>
		<category><![CDATA[placebo group]]></category>
		<category><![CDATA[recommended dose]]></category>
		<category><![CDATA[release tablets]]></category>
		<category><![CDATA[seizure frequency]]></category>
		<category><![CDATA[seizures]]></category>
		<category><![CDATA[treatment]]></category>
		<category><![CDATA[treatment period]]></category>

		<guid isPermaLink="false">http://blogjobs.biz/?p=9</guid>
		<description><![CDATA[Keppra has improved on its dosage, unveiling the Once-daily Keppra XR extended-release tablets which are now available in a new dosage strength, 750 mg. This enables doctors to simplify patients&#8217; treatment plans by decreasing the number of tablets they take each day. According to studies published in Epilepsy &#038; Behavior and Neurology, patients are more [...]<div class="addthis_toolbox addthis_default_style addthis_32x32_style" addthis:url='http://blogjobs.biz/2011/07/keppra-xr-dosage-strength-tablets-to-combat-partial-one-set-seizures/' addthis:title='Keppra XR Dosage Strength Tablets to Combat Partial One-Set Seizures' ><a class="addthis_button_google_plusone"></a><a class="addthis_button_facebook_like"></a><a class="addthis_button_stumbleupon"></a><a class="addthis_button_digg"></a><a class="addthis_button_compact"></a></div>]]></description>
		<wfw:commentRss>http://blogjobs.biz/2011/07/keppra-xr-dosage-strength-tablets-to-combat-partial-one-set-seizures/feed/</wfw:commentRss>
		<slash:comments>3</slash:comments>
		</item>
		<item>
		<title>How Nanosized Particles May Affect Skin Care Products</title>
		<link>http://blogjobs.biz/2010/03/how-nanosized-particles-may-affect-skin-care-products/</link>
		<comments>http://blogjobs.biz/2010/03/how-nanosized-particles-may-affect-skin-care-products/#comments</comments>
		<pubDate>Fri, 05 Mar 2010 04:59:06 +0000</pubDate>
		<dc:creator>Doctor Medical</dc:creator>
				<category><![CDATA[Health News]]></category>
		<category><![CDATA[Medical Gadgets]]></category>
		<category><![CDATA[Technology]]></category>
		<category><![CDATA[academy dermatologist]]></category>
		<category><![CDATA[adnan]]></category>
		<category><![CDATA[american academy of dermatology]]></category>
		<category><![CDATA[anti aging products]]></category>
		<category><![CDATA[clinical assistant professor]]></category>
		<category><![CDATA[cosmetic manufacturers]]></category>
		<category><![CDATA[cosmetic products]]></category>
		<category><![CDATA[department of dermatology]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[nanoparticles]]></category>
		<category><![CDATA[nanosized particles]]></category>
		<category><![CDATA[nanotechnology]]></category>
		<category><![CDATA[nasir]]></category>
		<category><![CDATA[skin care products]]></category>
		<category><![CDATA[unique properties]]></category>
		<category><![CDATA[university of north carolina]]></category>
		<category><![CDATA[voluntary ban]]></category>

		<guid isPermaLink="false">http://blogjobs.biz/2010/03/how-nanosized-particles-may-affect-skin-care-products/</guid>
		<description><![CDATA[The rapidly growing field of nanotechnology and its future use in cosmetic products holds both enormous potential and potential concern for consumers. Currently, major cosmetic manufacturers have imposed a voluntary ban on the use of nanoparticles in products while they await a ruling from the Food and Drug Administration (FDA) regarding the safety of this [...]<div class="addthis_toolbox addthis_default_style addthis_32x32_style" addthis:url='http://blogjobs.biz/2010/03/how-nanosized-particles-may-affect-skin-care-products/' addthis:title='How Nanosized Particles May Affect Skin Care Products' ><a class="addthis_button_google_plusone"></a><a class="addthis_button_facebook_like"></a><a class="addthis_button_stumbleupon"></a><a class="addthis_button_digg"></a><a class="addthis_button_compact"></a></div>]]></description>
		<wfw:commentRss>http://blogjobs.biz/2010/03/how-nanosized-particles-may-affect-skin-care-products/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>FDA Approves EMBEDA For Management of Moderate to Severe Chronic Pain</title>
		<link>http://blogjobs.biz/2009/08/fda-approves-embeda-for-management-of-moderate-to-severe-chronic-pain/</link>
		<comments>http://blogjobs.biz/2009/08/fda-approves-embeda-for-management-of-moderate-to-severe-chronic-pain/#comments</comments>
		<pubDate>Sat, 15 Aug 2009 08:34:24 +0000</pubDate>
		<dc:creator>Doctor Medical</dc:creator>
				<category><![CDATA[Health]]></category>
		<category><![CDATA[Health News]]></category>
		<category><![CDATA[Medication]]></category>
		<category><![CDATA[abuse liability]]></category>
		<category><![CDATA[analgesic effects]]></category>
		<category><![CDATA[chronic pain]]></category>
		<category><![CDATA[clinical significance]]></category>
		<category><![CDATA[euphoria]]></category>
		<category><![CDATA[food and drug administration]]></category>
		<category><![CDATA[food and drug administration fda]]></category>
		<category><![CDATA[hydrochloride]]></category>
		<category><![CDATA[inner core]]></category>
		<category><![CDATA[king pharmaceuticals]]></category>
		<category><![CDATA[morphine]]></category>
		<category><![CDATA[morphine sulfate]]></category>
		<category><![CDATA[naltrexone]]></category>
		<category><![CDATA[opioid receptor]]></category>
		<category><![CDATA[pellets]]></category>
		<category><![CDATA[proprietary technology]]></category>
		<category><![CDATA[receptor antagonist]]></category>
		<category><![CDATA[release capsules]]></category>
		<category><![CDATA[severe pain]]></category>
		<category><![CDATA[today announced that]]></category>

		<guid isPermaLink="false">http://blogjobs.biz/?p=240</guid>
		<description><![CDATA[King Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) has approved EMBEDA (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules for oral use, a long-acting Schedule II opioid analgesic for the management of moderate to severe pain when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. EMBEDA [...]<div class="addthis_toolbox addthis_default_style addthis_32x32_style" addthis:url='http://blogjobs.biz/2009/08/fda-approves-embeda-for-management-of-moderate-to-severe-chronic-pain/' addthis:title='FDA Approves EMBEDA For Management of Moderate to Severe Chronic Pain' ><a class="addthis_button_google_plusone"></a><a class="addthis_button_facebook_like"></a><a class="addthis_button_stumbleupon"></a><a class="addthis_button_digg"></a><a class="addthis_button_compact"></a></div>]]></description>
		<wfw:commentRss>http://blogjobs.biz/2009/08/fda-approves-embeda-for-management-of-moderate-to-severe-chronic-pain/feed/</wfw:commentRss>
		<slash:comments>2</slash:comments>
		</item>
	</channel>
</rss>

